SNTI: Senti Biosciences, Inc. Stock

by  •  • Comments Off on SNTI: Senti Biosciences, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 16.66
Enterprise Value ($M) 6.18
Book Value ($M) 15.99
Book Value / Share 3.31
Price / Book 1.04
NCAV ($M) -24.34
NCAV / Share -5.04
Price / NCAV -0.68

Profitability (mra)
Return on Invested Capital (ROIC) -1.40
Return on Assets (ROA) -0.59
Return on Equity (ROE) -1.06

Liquidity (mrq)
Quick Ratio 1.92
Current Ratio 1.92

Balance Sheet (mrq) ($M)
Current Assets 17.38
Assets 57.72
Liabilities 41.73
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99
02-14 13G Nantahala Capital Management, LLC 9.99
02-14 13G Nantahala Capital Partners Limited Partnership 5.91
12-04 13D/A New Enterprise Associates 15, L.P. 9.60 -90.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PUR
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUAN
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRAN
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 4,664 27,085 17.22
2025-03-06 3,797 22,220 17.09
2025-03-05 4,103 43,947 9.34
2025-03-04 15,035 73,882 20.35

(click for more detail)

Similar Companies
SNGX – Soligenix, Inc. SNPX – Synaptogenix, Inc.
SNSE – Sensei Biotherapeutics, Inc. SNYR – Synergy CHC Corp.
SONN – Sonnet BioTherapeutics Holdings, Inc.


Financial data and stock pages provided by
Fintel.io